Skip to main content
main-content
Oncology

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Red heart with stethoscope on blue background

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

Rheumatology

Mediterranean diet may be beneficial for people with axSpA

Mediterranean diet foods

Improved adherence to a Mediterranean dietary pattern is associated with a reduction in disease activity among people with axial spondyloarthritis, indicate findings from an Italian observational study.

Headlines from across medwireNews

16-09-2021 | Rheumatology | News | Article

Low rates of breakthrough SARS-CoV-2 infection after vaccination in people with RMDs

Preliminary findings from two studies point to low overall rates of breakthrough COVID-19 following vaccination in people with rheumatic and musculoskeletal diseases.

16-09-2021 | Rheumatology | News | Article

Booster dose may enhance COVID-19 vaccination response in people with autoimmune disease

Having a booster dose of vaccine against SARS-CoV-2 augments the humoral immune response in the majority of people with immune-mediated inflammatory diseases, suggest findings from a small study.

16-09-2021 | Diabetes | News | Article

Age-specific risk profiles may be needed for effective diabetes prevention

The influence metabolic factors have on type 2 diabetes risk falls as people get older, whereas lifestyle factors convey a greater risk with age, show data from a large, prospective cohort in China.

15-09-2021 | Rheumatology | News | Article

EULAR releases guidance on managing difficult-to-treat RA

EULAR has issued evidence-based points to consider for the management of difficult-to-treat rheumatoid arthritis.

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

15-09-2021 | Diabetes | News | Article

Risk factors for early retinopathy in type 2 diabetes revealed

Factors including insulin use and ethnicity can help predict who will develop proliferative diabetic retinopathy within 5 years after type 2 diabetes diagnosis, say researchers.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make medwireNews.com your preferred medical news resource.

Meet the team

Image Credits